Akoya Biosciences Past Earnings Performance
Past criteria checks 0/6
Akoya Biosciences's earnings have been declining at an average annual rate of -33.7%, while the Life Sciences industry saw earnings growing at 16.4% annually. Revenues have been growing at an average rate of 28% per year.
Key information
-33.7%
Earnings growth rate
59.5%
EPS growth rate
| Life Sciences Industry Growth | 21.5% |
| Revenue growth rate | 28.0% |
| Return on equity | -117.8% |
| Net Margin | -65.5% |
| Next Earnings Update | 13 May 2024 |
Recent past performance updates
Recent updates
Is Akoya Biosciences (NASDAQ:AKYA) Weighed On By Its Debt Load?
Feb 28
Investors Still Aren't Entirely Convinced By Akoya Biosciences, Inc.'s (NASDAQ:AKYA) Revenues Despite 31% Price Jump
Nov 25Akoya Biosciences Seeks Growth Despite Higher Operating Losses
May 30Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
May 11Akoya Biosciences and AstraZeneca ink collaboration agreement
Jun 04Revenue & Expenses BreakdownBeta
How Akoya Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 97 | -63 | 82 | 22 |
| 30 Sep 23 | 91 | -71 | 84 | 24 |
| 30 Jun 23 | 85 | -76 | 85 | 24 |
| 31 Mar 23 | 79 | -73 | 83 | 23 |
| 31 Dec 22 | 75 | -71 | 80 | 23 |
| 30 Sep 22 | 70 | -69 | 78 | 22 |
| 30 Jun 22 | 64 | -63 | 72 | 21 |
| 31 Mar 22 | 60 | -51 | 61 | 18 |
| 31 Dec 21 | 55 | -44 | 51 | 16 |
| 30 Sep 21 | 52 | -34 | 39 | 13 |
| 30 Jun 21 | 48 | -28 | 31 | 11 |
| 31 Mar 21 | 44 | -28 | 26 | 10 |
| 31 Dec 20 | 42 | -22 | 24 | 10 |
| 31 Dec 19 | 42 | -18 | 26 | 9 |
Quality Earnings: AKYA is currently unprofitable.
Growing Profit Margin: AKYA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AKYA is unprofitable, and losses have increased over the past 5 years at a rate of 33.7% per year.
Accelerating Growth: Unable to compare AKYA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AKYA is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-9.3%).
Return on Equity
High ROE: AKYA has a negative Return on Equity (-117.77%), as it is currently unprofitable.